Novartis Commits $1.7 Billion to AI-Driven Allergy Drug Discovery Partnership with Relation Therapeutics
核心洞察
Novartis has entered a $1.7 billion partnership with Relation Therapeutics (搜索) to develop treatments for allergic diseases (搜索) using AI-driven drug discovery platforms that analyze patient datasets and human tissue to identify genetic triggers (搜索).
The deal includes $55 million upfront payment with potential milestone payments up to $1.7 billion plus tiered royalties, representing part of Novartis' broader strategy to build a resilient pipeline beyond 2025.
Relation's AI technology aims to nominate genetically validated drug targets faster than traditional discovery methods, potentially improving success rates in a field where roughly 75% of drugs fail in phase 2 trials.
Novartis has announced a major $1.7 billion partnership with British pharmaceutical company Relation Therapeutics (搜索) to develop new treatments for allergic diseases (搜索) using artificial intelligence-driven drug discovery platforms. The Swiss pharmaceutical giant will pay $55 million upfront to combine its immuno-dermatology expertise with Relation's AI engine, which analyzes patient datasets including human tissue to uncover the genetic triggers (搜索) behind allergic diseases.
Strategic Investment in AI-Native Drug Discovery
The partnership represents Novartis' growing conviction that data-intensive platforms may reshape how immunology drugs are developed. Relation Therapeutics (搜索), backed by DCVC and Nvidia's NVentures, could earn milestone payments up to $1.7 billion alongside tiered royalties tied to future product sales.
Relation's technology is designed to nominate genetically validated drug targets faster than traditional discovery paths, potentially raising the probability of success compared with conventional methods. According to Relation CEO David Roblin, roughly 75% of drugs entering phase 2 trials fail for safety or efficacy reasons, which he attributed to limited biological clarity at the start of development.
Building Pipeline Resilience Beyond 2025
The AI partnership forms part of Novartis' broader strategy to build a more resilient pipeline as generic competitors threaten three core medicines beyond 2025, including blockbuster heart therapy Entresto. Earlier this year, the company made several major acquisitions, including Avidity Biosciences (搜索) in a $12 billion deal - its largest in more than a decade - before adding Tourmaline Bio for $1.4 billion to secure an experimental treatment aimed at lowering systemic inflammation.
The company also agreed to buy Regulus Therapeutics for as much as $1.7 billion and expanded its cardiology footprint through Anthos Therapeutics, gaining access to a preventative stroke candidate.
Addressing Significant Unmet Medical Need
The commercial upside for the Relation partnership could be meaningful given that atopic diseases (搜索) affect hundreds of millions of patients worldwide and remain underserved despite heavy R&D spending. The collaboration emerged from discussions between Relation CEO David Roblin and Novartis biomedical research president Fiona Marshall at the JP Morgan healthcare conference, where the idea of a joint research plan gradually evolved into the current transaction.
Relation has already executed a similar partnership with GSK in 2024, suggesting accelerating demand for AI-native platforms as global drugmakers look to improve the pace and economics of long-term discovery.
Market Response and Outlook
Investors saw little immediate price reaction to the announcement, although Novartis shares are up roughly 21% this year. JPMorgan (搜索) recently upgraded Novartis shares to Overweight from Neutral, raising the price target to CHF125 from CHF95 based on positive sentiment regarding the company's outlook for 2026.